CBS 2019
CBSMD教育中心
English

推荐文献

科研文章

荐读文献

A Novel Algorithm for Treating Chronic Total Coronary Artery Occlusion Association of preoperative glucose concentration with myocardial injury and death after non-cardiac surgery (GlucoVISION): a prospective cohort study Discharge Against Medical Advice After Percutaneous Coronary Intervention in the United States The year in cardiovascular medicine 2020: interventional cardiology Frequency, Regional Variation, and Predictors of Undetermined Cause of Death in Cardiometabolic Clinical Trials: A Pooled Analysis of 9259 Deaths in 9 Trials Mortality Differences Associated With Treatment Responses in CANTOS and FOURIER: Insights and Implications Catheterization Laboratory Considerations During the Coronavirus (COVID-19) Pandemic: From the ACC’s Interventional Council and SCAI Coronary Angiography after Cardiac Arrest without ST-Segment Elevation Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease Impact of lesion complexity on peri-procedural adverse events and the benefit of potent intravenous platelet adenosine diphosphate receptor inhibition after percutaneous coronary intervention: core laboratory analysis from 10 854 patients from the CHAMPION PHOENIX trial
|<<... 16 17 18 19 20 21 22 ...>>|

Guideline26 August 2017

JOURNAL：European Heart Journal Article Link

2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries Endorsed

V. Aboyans, J-B Ricco, M-L E. L. Bartelink et al Keywords: Prevention; Peripheral Vascular Intervention; Peripheral Arterial Diseases

Full Text PDF

>CBS CBS 2019

> CBS 2019

> CBS 2019 注册

> CBS 2019 会议日程

> CBS 2019 学术征集

> CBS 2019 热点

 CBSMD

> CBSMD 网站注册

> 教育中心

> 荐读文献

> Top 10 阅读文献

> 文献导读
CBS 2019 CBS 2019 主席团 教育中心 科研动态
Copyright ⓒ CBS MD Nanjing China. All rights reserved. 京ICP备16025898号-11
联系我们| Top